Foundation Medicine-B (02616.HK): CS5007 (EGFR/HER3 dual-specific ADC) global multi-center Phase I clinical trial initiated.

The Zhitong Finance APP reported that Cornerstone Pharmacy-B (02616.HK) announced that its global multicenter Phase I clinical trial for the core candidate drug CS5007 (EGFR/HER3 bispecific antibody-drug conjugate [ADC]) has officially obtained approval from the Australian Human Research Ethics Committee (HREC). This not only marks the full-scale initiation of global clinical development for CS5007, but also signifies that the company's Pipeline 2.0 strategy is accelerating, with significant momentum entering the clinical fast lane, which is expected to continue to inject confidence into medium to long-term growth.